Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine.

Nat Commun · 2022 · PMC8956637 · PMID 35338131

Europe PMC DOI

hedged sentence

0.0022

closest p · 0.0× alpha

0.0022

boldest claim

The sentences

highly significantp = 0.0022actually significant

This decrease was highly significant in the naive group (N-peptide, p = 0.0022, R-, p = <0.0003, and C-, p = 0.0367) whereas it was non-significant in the semi-immune group (N-peptide, p = 0.902, R- p = 0.263, and C-, p = 0.371) (Fig. 4 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.